Prof.RonaldMa Hong Kong, China

Prof.RonaldMa
Ronald Ma is a clinician-scientist and a specialist in Endocrinology, Metabolism and Diabetes. He completed his medical training at the University of Cambridge, UK and trained in Internal Medicine in London, followed by endocrinology fellowship training in Hong Kong. He then pursued a research fellowship in diabetic complications at the Joslin Diabetes Center, Harvard Medical School, Boston, USA. Dr Ma’s research focuses on the epidemiology and genetics of diabetes and its complications, gestational diabetes, polycystic ovary syndrome, and the developmental origins of diabetes. He is currently leading a multi-disciplinary project team to leverage on the Hong Kong Diabetes Register and accompanying biobank to identify novel molecular markers for diabetic complications, and is the principal investigator of the Hong Kong Diabetes Biobank. He has also initiated several mother-offspring cohorts to examine the long-term effects of gestational diabetes and PCOS, and multi-omic studies to identify novel biomarkers. He is also leading local initiatives to enhance local biobanking capacity in Hong Kong and related research. He has published over 450 research articles in international peer-reviewed journals (>35,000 citations, H-index 79). He received the Croucher Senior Medical Research Fellowship (2020) to further his research on Precision Medicine in Diabetes, and the Xiaoren Pan Distinguished Research Award for Epidemiology of Diabetes in Asia from the Asian Association for the Study of Diabetes (AASD). Dr Ma plays an active role in diabetes advocacy. He is a Past President of the International Diabetes Epidemiology Group, a Past President of Diabetes Hongkong, and member of the Executive Board, the Asian Association for the Study of Diabetes (AASD). He has served as a Commissioner on the Lancet Commission on Diabetes, the International Federation of Gynecology and Obstetrics (FIGO) Pregnancy and NCD Committee, as well as council member of IADPSG. He has served as consultant for the WHO on childhood obesity, the International Diabetes Federation, as well as FIGO on NCD prevention. He serves on the Steering Committee for Prevention and Control of Non-communicable Diseases for the Hong Kong Health Bureau. He led the workgroup on Type 1 Diabetes in Adults for the IDF Diabetes Atlas, and in an international initiative on Precision Medicine in Diabetes. He currently serves as editorial board member of PLoS Medicine, Diabetologia, Diabetes, Obesity Reviews, Journal of Diabetes Investigation and Maternal-Fetal Medicine.

21 MARCH

Time Session
08:30
10:00
Precision Medicine in Endocrinology
  • Shih-Li SuTaiwan Speaker Sex-Specific Approaches in Precision Medicine: Advancing Endocrinology CareSex differences are fundamental determinants of endocrine physiology and disease. Conventional approaches that treat men and women as biologically equivalent overlook variations in hormonal regulation, immune response, organ function, and pharmacologic metabolism. Precision medicine in endocrinology integrates these sex-specific biological and environmental factors to achieve individualized care. Emerging evidence shows that women are more prone to autoimmune thyroid disease, prolactinoma, and osteoporosis, largely due to estrogen-enhanced immune activity and X-chromosome dosage effects. Men, by contrast, experience higher rates of hypogonadism, visceral obesity, and aggressive endocrine tumors, reflecting androgen decline and single X-chromosome vulnerability. Hormonal effects, such as menopause-related bone loss, are often reversible, whereas chromosomal influences—such as those seen in Turner and Klinefelter syndromes—are irreversible and genetically determined. Pharmacokinetic and pharmacodynamic disparities further highlight the need for sex-informed dosing. Women generally have higher CYP3A4 activity and altered drug binding via increased sex hormone–binding globulin. In Asian populations, genetic polymorphisms, including the high prevalence of BRAF^V600E^ mutations in papillary thyroid cancer and variable androgen receptor CAG repeats, demand region-specific precision strategies. Sex-specific precision endocrinology moves beyond a uniform model of care by recognizing biological sex as a key variable in disease risk and treatment response. Incorporating sex-stratified analyses, adjusted diagnostic thresholds, and personalized pharmacotherapy can enhance diagnostic accuracy and therapeutic safety. For Asia, integrating genetic and environmental diversity is essential to advance equitable, individualized endocrine care.
  • Miyuki KataiJapan Speaker From the Bedside to the Digital World: Precision Medicine in Endocrinology with Al and ICT
  • Ronald MaHong Kong, China Speaker Precision Medicine in Diabetes: Perspectives from AsiaChallenging Cases in Endocrinology
201DE

22 MARCH

Time Session
13:30
14:00
Case Challenges
201BC